Western Blot: hnRNP F Antibody [NBP1-33607] - Sample (30 ug of whole cell lysate) A: Hep G2 10% SDS PAGE; antibody diluted at 1:1000.
Immunocytochemistry/ Immunofluorescence: hnRNP F Antibody [NBP1-33607] - Paraformaldehyde-fixed A431, using hnRNP F (NBP1-33607) antibody at 1:200 dilution.
Immunohistochemistry-Paraffin: hnRNP F Antibody [NBP1-33607] - Paraffin-embedded mouse uterus. hnRNP F antibody [N1N3] diluted at 1:500.
Immunohistochemistry-Paraffin: hnRNP F Antibody [NBP1-33607] - Paraffin-embedded A549 Xenograft, using antibody at 1:100 dilution.
Immunoprecipitation: hnRNP F Antibody [NBP1-33607] - Immunoprecipitation of hnRNP F protein from 293T whole cell extracts using 5 ug of hnRNP F antibody [N1N3]. Western blot analysis was performed using hnRNP F antibody ...read more
46 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
0.1M Tris (pH 7), 0.1M Glycine, 10% Glycerol
Immunogen affinity purified
Alternate Names for hnRNP F Antibody
heterogeneous nuclear ribonucleoprotein F
HNRPFHnRNP F protein
Nucleolin-like protein mcs94-1
Heterogeneous nuclear ribonucleoproteins (hnRNPs) constitute a set of polypeptides that contribute to pre-mRNA processing and transport, and also bind heterogeneous nuclear RNA (hnRNA), which are the transcripts produced by RNA polymerase II. hnRNP complexes are the major constituents of the spliceosome and in particular, the hnRNP A1 protein is one of the major premRNA/ mRNA binding proteins and also one of the most abundant proteins in the nucleus. hnRNP A1 and A2/B1 regulate the processing of pre-mRNA by directly antagonizing the association of various splicing factors and by influencing the splice site selection on pre-mRNA. The majority of hnRNP proteins components are localized to the nucleus; however some shuttle between the nucleus and the cytoplasm. Most hnRNP proteins, including hnRNP C1 and C2, contain one or more RNA binding domains and are implicated in the processing of pre-mRNA. hnRNPs F and H are largely related factors that preferentially associate with poly(rG) regions on RNA. Isoforms of these proteins are often generated by alternative processing of the premRNA and by posttranslational modifications such as phosphorylation on serines and threonines and methylation of arginines.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
⚠ WARNING: This product can expose you to chemicals including mercury, which is known to the State of California to cause reproductive toxicity with developmental effects. For more information go to www.P65Warnings.ca.gov.
Publications for hnRNP F Antibody (NBP1-33607)(2)
We have publications tested in 2 confirmed species: Human, Mouse.
We have publications tested in 3 applications: IP, KD, WB.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our hnRNP F Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.